Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

PloS one - 1 Jan 2016

Costa-Cabral Sara, Brough Rachel, Konde Asha, Aarts Marieke, Campbell James, Marinari Eliana, Riffell Jenna, Bardelli Alberto, Torrance Christopher, Lord Christopher J, Ashworth Alan

Abstract excerpt

Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent kinase, CDK1. This was discovered using parallel siRNA screens in KRAS mutant and wild type colorectal isogenic tumour cells and subsequently validated in a genetically diverse panel of 26...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, Lethal
Share to CDC2 Protein Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinases

Share to G1 Phase Cell Cycle Checkpoints

Share to High-Throughput Screening Assays

Share to Imidazoles

Share to Quinolines

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 26881434
DOI: 10.1371/journal.pone.0149099
PMCID: PMC4755568

Genes

KRAS
CDK1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.PMID 26881434Read ↗

Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.Semantic proximity Read ↗

Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators.Semantic proximity Read ↗

Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers.Semantic proximity Read ↗

Current Strategies and Future Dimensions in the Development of KRAS Inhibitors for Targeted Anticancer Therapy.Semantic proximity Read ↗

Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor ResistanceSemantic proximity Read ↗

Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.Semantic proximity Read ↗

Changes in the Transcriptome and Synthetic Lethal Dependencies Following <i>KRAS</i> Mutant Expression Reveal Profound Tissue-SpecificitySemantic proximity Read ↗

An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development.Semantic proximity Read ↗

Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK.Semantic proximity Read ↗

From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design.Semantic proximity Read ↗

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition.Semantic proximity Read ↗

Targeting cancer with small molecule pan-KRAS degradersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.